Genmab — April 2017

[bibob]

Ca. 67 dg. fra 23 februar. Omkring D. 1 maj.

[E_L]

Could be this week, press release Genmab February 24 said "A final decision by the European Commission is anticipated within two months."

[E_L]

And NICE /UKsecond commitee meeting April 20, but i dont know if they will make any announcements, as it says Expected
publication date July 2017

[bibob]

http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/004077/WC500222148.pdf Nederst på siden står der 67 dg.

[digafarm]

Det må så være senest d. 27/4

[E_L]

EMA must be the correct one indeed. Guess Rachel didn't read the small print A few extra days of nervousness...

[JKY_VH]

I'm not worried about the approval. Dont worry be happy:-)

[digafarm]

Probably the friday news we have been longing for in two weeks time

[bibob]

God morgen

[bibob]

Ser ud til at GMXAY alligevel blev handlet i går. + 0,67. %.

[JKY_VH]

God morgen

[transalp]

Go morgen

[E_L]

FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer

[Helge_LarsenPI-redaktør]

God morgen.

[Sibelius]

@GlobalMacro, Thanks for sharing your thoughts. Totally agree with your line of thought re how investors and analysts need to see gradual proof of the pudding before upping targets and expectations.

[Sibelius]

I also agree that it is unlikely that Genmab remain independent for ten years more - or five for that matter.

[Sibelius]

However, before getting lost in P/E calculations etc., we should also consider what the strategy of the company is, and how this will change the operations and earings multiples.

[Sibelius]

Genmab will - if strategy becomes action and reality - become a completely different animal.

[Sibelius]

This will include a lot more investment - and risk - in new R&D. Also, taking greater responsibility for approvals, market launch and global sales of new products will lead to much higher leverage and roll-out risks.

[Sibelius]

It is quite difficult to factor all this in to the current stock price and current analyst targets. This is why targets are quite modest, as most are concerned with the next 4-6 years in their forecasts.